A Study to Investigate the Efficacy of Pain Bloc-R in Healthy Participants With Non-pathological Aches and Discomfort

A randomized, double-blind, placebo-controlled, cross-over pilot study to investigate the efficacy of Pain Bloc-R in healthy participants with non-pathological aches and discomfort. The study will have 3 study periods. During each study period, eligible participants will consume either Pain Bloc-R, comparator product, or placebo for 7 days during each study period (1 product per study period), with a 1-week washout period in between each period. The primary objective is the comparison of change in unresolved aches and discomfort from pre-supplement to Day 7 between the Pain Bloc-R, comparator, and placebo, as assessed by the Brief Pain Inventory (BPI) questionnaire.


Eligibility Criteria:
Inclusion Criteria:

1. Males and females 18-65 years of age, inclusive
2. BMI of 18-32.5 kg/m2, inclusive
3. Individuals with occupational (construction workers, manual labourers, athletes) and non-occupational unresolved aches and discomfort for at least 2 weeks
4. Individuals on non-prescription, OTC medication for unresolved aches and discomfort and are willing to undergo a washout determined by the QI based on dose and frequency prior to enrollment
5. Female participants not of child bearing potential, defined as females who have had a hysterectomy or bilateral oophorectomy, bilateral tubal ligation, total endometrial ablation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) or, Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
   * Double-barrier method
   * Intrauterine devices
   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   * Vasectomy of partner at least 6 months prior to screening
6. Healthy as determined by laboratory results and medical history as assessed by the QI
7. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
8. Agrees to comply with study procedures
9. Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
2. Anticipated problems or allergy to any ingredients in the investigational products
3. Allergy to rescue medication
4. Have chronic disease conditions causing chronic pain
5. Uncontrolled high and low blood pressure
6. Uncontrolled blood sugar levels
7. Clinically significant abnormal laboratory results at screening
8. Prescribed medications used to help with aches and discomfort (Section 7.3.1)
9. OTC medications and supplements taken to help with aches and discomfort (Section 7.3.2)
10. Autoimmune disease or if immune-compromised (i.e. HIV-positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C-positive)
11. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow-up that is negative. Volunteers with cancer in full remission for more than 5 years after diagnosis are acceptable after review by QI
12. History of mental illness that might impair the ability of participants to provide written informed consent
13. Current or history of bleeding disorders
14. Current or history of liver or kidney disease as assessed by QI on a case by case basis.
15. Current or pre-existing unstable thyroid condition. Treatment on a stable dose medication for over one year will be reviewed on a case-by-base basis by the QI
16. Surgical procedures which may impact the study outcomes within the past 3 months to be assessed by the QI
17. Medicinal marijuana
18. Recreational marijuana; dose and frequency to be assessed by QI
19. Alcohol intake \>2 standard drinks per day or \>10 standard drinks per week
20. Illicit drug use in the past 6 months as assessed by the QI
21. Participation in clinical trials within 30 days prior to screening visit
22. Blood donation during or within 30 days after conclusion of clinical trial
23. Any other active or unstable medical condition, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant.